EW Stock Overview
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally.
Edwards Lifesciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$96.13|
|52 Week High||US$131.73|
|52 Week Low||US$91.52|
|1 Month Change||-18.80%|
|3 Month Change||-9.26%|
|1 Year Change||0.71%|
|3 Year Change||70.26%|
|5 Year Change||152.42%|
|Change since IPO||6,891.27%|
Recent News & Updates
Capital Investment Trends At Edwards Lifesciences (NYSE:EW) Look Strong
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Is Now The Time To Put Edwards Lifesciences (NYSE:EW) On Your Watchlist?
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Edwards Lifesciences Corporation (NYSE:EW) Shares Could Be 33% Above Their Intrinsic Value Estimate
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Edwards Lifesciences...
|EW||US Medical Equipment||US Market|
Return vs Industry: EW exceeded the US Medical Equipment industry which returned -16.2% over the past year.
Return vs Market: EW exceeded the US Market which returned -12.9% over the past year.
|EW Average Weekly Movement||6.0%|
|Medical Equipment Industry Average Movement||10.5%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: EW is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: EW's weekly volatility (6%) has been stable over the past year.
About the Company
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy.
Edwards Lifesciences Fundamentals Summary
|EW fundamental statistics|
Is EW overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EW income statement (TTM)|
|Cost of Revenue||US$1.25b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||2.47|
|Net Profit Margin||28.72%|
How did EW perform over the long term?See historical performance and comparison
Is Edwards Lifesciences undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: EW ($96.13) is trading above our estimate of fair value ($84.07)
Significantly Below Fair Value: EW is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: EW is poor value based on its PE Ratio (38.8x) compared to the US Medical Equipment industry average (35.2x).
PE vs Market: EW is poor value based on its PE Ratio (38.8x) compared to the US market (15.1x).
Price to Earnings Growth Ratio
PEG Ratio: EW is poor value based on its PEG Ratio (3.7x)
Price to Book Ratio
PB vs Industry: EW is overvalued based on its PB Ratio (10.2x) compared to the US Medical Equipment industry average (2.4x).
How is Edwards Lifesciences forecast to perform in the next 1 to 3 years based on estimates from 24 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EW's forecast earnings growth (10.5% per year) is above the savings rate (1.9%).
Earnings vs Market: EW's earnings (10.5% per year) are forecast to grow slower than the US market (12.5% per year).
High Growth Earnings: EW's earnings are forecast to grow, but not significantly.
Revenue vs Market: EW's revenue (10.1% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: EW's revenue (10.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EW's Return on Equity is forecast to be high in 3 years time (22.4%)
How has Edwards Lifesciences performed over the past 5 years?
Past Performance Score6/6
Past Performance Score 6/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EW has high quality earnings.
Growing Profit Margin: EW's current net profit margins (28.7%) are higher than last year (19%).
Past Earnings Growth Analysis
Earnings Trend: EW's earnings have grown by 18.3% per year over the past 5 years.
Accelerating Growth: EW's earnings growth over the past year (80.8%) exceeds its 5-year average (18.3% per year).
Earnings vs Industry: EW earnings growth over the past year (80.8%) exceeded the Medical Equipment industry 16.1%.
Return on Equity
High ROE: EW's Return on Equity (26.3%) is considered high.
How is Edwards Lifesciences's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: EW's short term assets ($3.2B) exceed its short term liabilities ($949.9M).
Long Term Liabilities: EW's short term assets ($3.2B) exceed its long term liabilities ($1.6B).
Debt to Equity History and Analysis
Debt Level: EW has more cash than its total debt.
Reducing Debt: EW's debt to equity ratio has reduced from 31% to 10.2% over the past 5 years.
Debt Coverage: EW's debt is well covered by operating cash flow (289.5%).
Interest Coverage: EW's interest payments on its debt are well covered by EBIT (2348.7x coverage).
What is Edwards Lifesciences's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EW's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EW's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EW's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EW's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as EW has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Mussallem (68 yo)
Mr. Michael A. Mussallem, also known as Mike, has been Chairman and Chief Executive Officer of Edwards Lifesciences Corporation since 2000. He also serves as an Advisor at Incube Management, LLC. Mr. Mussa...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD13.61M) is about average for companies of similar size in the US market ($USD13.34M).
Compensation vs Earnings: Mike's compensation has increased by more than 20% in the past year.
Experienced Management: EW's management team is seasoned and experienced (8.3 years average tenure).
Experienced Board: EW's board of directors are considered experienced (6.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: EW insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Edwards Lifesciences Corporation's employee growth, exchange listings and data sources
- Name: Edwards Lifesciences Corporation
- Ticker: EW
- Exchange: NYSE
- Founded: 1958
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$59.769b
- Shares outstanding: 621.75m
- Website: https://www.edwards.com
Number of Employees
- Edwards Lifesciences Corporation
- One Edwards Way
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/24 00:00|
|End of Day Share Price||2022/05/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.